Table 1 Patient characteristics
Stz/5-FU n = 32 | PRRT n = 56 | Everolimus n = 52 | |
|---|---|---|---|
Age, years Median (range) | 65 (28–83) | 63 (29–79) | 66 (41–81) |
Sex | |||
Female | 20 (63) | 26 (46) | 31 (60) |
Primary focus (%) | |||
Pancreas | 22 (67) | 18 (32) | 17 (33) |
Small intestine | 1 (3) | 26 (46) | 19 (37) |
Lung | 3 (9) | 1 (2) | 9(17) |
Rectum | 1(3) | 3 (5) | |
Kidney | 1(2) | ||
Duodenum | 1(3) | 1(2) | |
Pheochromocytoma | 1(2) | ||
Gastric | 1(3) | ||
Thymus | 1(2) | ||
Unknown | 3 (9) | 5 (9) | 6 (12) |
Stage | |||
Regional | 2 (6) | 1 (2) | 4 (8) |
Distant | 30 (94) | 55 (98) | 48 (92) |
Previous treatment with PRRT | 1 (3) | – | 25 (48) |
Previous treatment with stz/5FU | – | 12 (21) | 18 (35) |
Previous treatment with everolimus | 1 (3) | 1 (2) | – |
Previous treatment with stz/5FU and PRRT | – | – | 20 (38) |
Number of previous treatmentsa Median (mean) | 0 (0,6) | 1,9 (2,0) | 3 (2,6) |
Follow-up time Months (min-max) | 47 (5–113) | 48 (10–98) | 14 (4–77) |